PALO ALTO, Calif. and BHOPAL, India, Oct. 7, 2015 /PRNewswire/ -- The Chirayu Medical College and Hospital (CMCH) in Bhopal, India, is among the first cancer treatment centers around the world to acquire the new VitalBeam™ platform from Varian Medical Systems (NYSE: VAR), offering clinics a modular technology package for affordable, high-quality, high-throughput radiotherapy, and for expanding clinical capabilities over time.
Varian recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as well as the CE Mark for the VitalBeam platform. In addition to the CMCH in India, treatment centers in the U.S. and Europe have now ordered the system, which incorporates many of the innovations Varian developed to enhance the precision, safety, and speed of treatment on its popular TrueBeam® radiotherapy system.
The VitalBeam system at the CMCH will anchor a new radiotherapy department there, complementing existing medical oncology services. "We are looking to increase the capacity in our region for helping cancer patients with the most advanced treatments possible and we are making efforts to provide patients with the best available treatments in the world," said Ajay Goenka, M.D., owner of CMCH. "We chose VitalBeam because we wanted something with the advantages of the TrueBeam platform that would enable us to go beyond basic intensity-modulated radiotherapy."
"The VitalBeam system will enable us to complete image-guided treatments quickly—in as little as 2-4 minutes when using advanced capabilities like RapidArc®—and to shape the radiation dose very precisely," added T. P. Sahoo, M.D., physician at the CMCH. "That will be good news for the cancer patients of our region."
According to Dr. Sahoo, the clinical team at the CMCH will use the VitalBeam system to treat patients with tumors in vital locations where toxicity to healthy tissues must be minimized. "I anticipate that we will use it curatively, to treat head and neck, brain, pancreatic, and other abdominal malignancies, because these are common cancers that can be addressed with advanced radiotherapy."
"Our goal, with this platform, was to help increase access to quality cancer care around the world," said Kolleen Kennedy, president of Varian's Oncology Systems business. "We are gratified to work with institutions like the Chirayu Medical College in bringing advanced, image-guided radiotherapy to more cancer patients."
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit www.varian.com or follow us on Twitter.
About the Chirayu Medical College & Hospital (CMCH)
CMCH is a teaching hospital attached to Chirayu Medical College in Bhopal, India. The hospital, which is 3-4 years old, incorporates multiple specialty departments (including oncology), emergency room, and an intensive care unit. There are 671 beds with plans to add another 200-300 beds over the next four years. The hospital and medical college complex is spread over 25.6 acres of land located on the Bhopal-Indore Highway, in a lush green surroundings and easily approachable from airport and railway stations.
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the ability of the company's technology and products to treat cancer or improve outcomes; and any statements using the terms "will," "looking to," "would," "must," "can," "goal," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Varian Medical Systems
+1 (650) 424-6444
SOURCE Varian Medical Systems